Objective: To determine whether single-fraction and combination modified-live bovine respiratory syncytial virus (BRSV) vaccines commercially licensed for parenteral administration could stimulate protective immunity in calves after intranasal administration.
Design: Randomized controlled trial.
Animals: 39 calves.
Procedures: Calves were separated from dams at birth, fed colostrum with a minimal concentration of antibodies against BRSV, and maintained in isolation. In 2 preliminary experiments, 9-week-old calves received 1 (n = 3) or 2 (3) doses of a single-component, modified-live BRSV vaccine or no vaccine (8 control calves in each experiment), and were challenged with BRSV 21 days after vaccination. In a third experiment, 2-week-old calves received combination modified-live virus (MLV) vaccines with or without BRSV and calves were challenged with BRSV 8 days later. Calves were euthanized, and lung lesions were measured. Immune responses, including serum and nasal antibody and nasal interferon-alpha concentrations, were assessed.
Results: BRSV challenge induced signs of severe clinical respiratory tract disease, including death and pulmonary lesions in unvaccinated calves and in calves that received a combination viral vaccine without BRSV. Pulmonary lesions were significantly less severe in BRSV-challenged calves that received single or combination BRSV vaccines. The proportion of calves that shed virus and the peak virus titer was decreased, compared with control calves. Protection was associated with mucosal IgA antibody responses after challenge.
Conclusions And Clinical Relevance: Single and combination BRSV vaccines administered intranasally provided clinical protection and sparing of pulmonary tissue similar to that detected in response to parenteral delivery of combination MLV and inactivated BRSV vaccines previously assessed in the same challenge model.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2460/javma.230.2.233 | DOI Listing |
Vet Sci
December 2024
Department of Animal Sciences and Center for Nutrition and Pregnancy, North Dakota State University, Fargo, ND 58108, USA.
Two experiments assessed the effects of providing a vitamin and mineral supplement to gestating beef heifers on concentrations of immunoglobulins (Ig) in colostrum and calf serum 24 h after feeding maternal colostrum (Exp. 1) or a colostrum-replacement product (Exp. 2).
View Article and Find Full Text PDFBiol Trace Elem Res
December 2024
Agricultural Research Service-Poisonous Plant Research Lab, USDA, Logan, UT, 84341, USA.
Supranutritional Se supplementation may improve immune responses in beef cattle. Immunity is compromised in beef cattle during the periparturient period. This study aims to determine the best time during pregnancy to supplement beef cows with Se-yeast to optimize humoral immunity at parturition.
View Article and Find Full Text PDFViruses
November 2024
Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou 730030, China.
Bovine respiratory syncytial virus (BRSV) is an enveloped RNA virus that utilizes clathrin-mediated endocytosis for cell entry and is a significant pathogen in bovine respiratory disease (BRD). Heat shock protein family A member 4 (HSPA4), a member of the HSP70 family, is known to be involved in the progression of various cancers. However, its role in virus entry has not been previously explored.
View Article and Find Full Text PDFViruses
November 2024
Department of Veterinary Pathobiology, Oklahoma State University, Stillwater, OK 74078, USA.
Bovine respiratory syncytial virus (BRSV) is a major respiratory pathogen in cattle and is relevant to the livestock industry worldwide. BRSV is most severe in young calves and is often associated with stressful management events. The disease is responsible for economic losses due to lower productivity, morbidity, mortality, and prevention and treatment costs.
View Article and Find Full Text PDFVaccines (Basel)
October 2024
Hipra Scientific S.L.U., Avda. La Selva 135, 17170 Amer, Spain.
A new multivalent vaccine (DIVENCE), containing live gE/tk double-gene-deleted BoHV-1, live-attenuated BRSV, inactivated PI3, and BVDV-1, and BVDV-2 recombinant proteins, has been designed to protect cattle against the main viral pathogens associated with bovine respiratory disease (BRD). The aim of this study was to demonstrate the efficacy of DIVENCE against BRD in field conditions. A total of 360 animals from three different farms were included in this study.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!